Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug ruxolitinib keeps flowing to stable patients in rollover trial

NCT ID NCT02955940

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 18, 2026 · Updated 3 times

Summary

This study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, and the main goal is to monitor safety and side effects, not to test new effectiveness. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ruxolitinib (a targeted cancer drug, also known as Jakafi), sometimes given with capecitabine or regorafenib
What this could lead to
If successful, this study helps ensure patients who are already benefiting from ruxolitinib can keep taking it without interruption, while gathering more safety data.
What could go wrong
This is a small rollover study (10 people) that does not test new effectiveness. It only continues existing treatment and monitors side effects, so it won't prove whether ruxolitinib works for these cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

10 people

The number who actually took part.

Started

Nov 2016

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated. * Currently tolerating treatment in the parent protocol. * Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator. * Have at least stable disease, as determined by the investigator. * Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements. Exclusion Criteria: * Has been permanently discontinued from study treatment in the parent study for any reason. * Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal cancer colorectal neoplasm lung cancer lung neoplasm malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Colorectal cancer (CRC) Lung cancer Pancreatic cancer

Contacts and locations

Locations

  • Instytut Hematologii I Transfuzjologii

    Warsaw, 02-776, Poland

  • New York Oncology Hematology Pc.

    Clifton Park, New York, 12065, United States

  • Renovatio Clinical Consultants Llc

    The Woodlands, Texas, 77380, United States

  • Samodzielny Publiczny Szpital Kliniczny

    Lublin, 20-081, Poland

  • Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny Hematologii

    Krakow, 31-501, Poland

  • Tennessee Oncology

    Nashville, Tennessee, 37203, United States

  • UCLA Healthcare Hematology-Oncology

    Santa Monica, California, 90404, United States

  • University of Louisville

    Louisville, Kentucky, 40202, United States

  • University of Texas M. D. Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.